OCGN - Conference and earnings call announcements

MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in November 2026. Stifel 2026 Healthcare ConferenceLocation: New York, NYDate: Thursday, November 12, 2026Time: 10:00–10:30 a.m. ETFormat: PresentationPresenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen Cell & Gene Leaders Live 2026Location: The Shard, London, UKDate: Sunday, November 15, 2026Time: 3:15–4:00 p.m. GMT Format: Panel discussionPresente

MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences. Euretina Innovation Spotlight (EIS) 2026Location: VIECON, Vienna, AustriaDate: Wednesday, September 30, 2026Time: 2:34 p.m. CESTFormat: Company presentationTitle: Ocugen Company OverviewPresenter: Abhi Gupta, Executive Vice President, Commercial and Business Development, Ocugen 26th Euretina Congress 2026 Location: VIECON, Vienna, AustriaDate: Thursday, October 1, 2026Time: 1:

MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of its executive leadership team will present at two upcoming investor and industry conferences. H.C. Wainwright: Biotech on Tap 2026Location: EY Auditorium, Munich, GermanyDate: Thursday, October 1, 2026Time: 1:45–2:30 p.m. CESTFormat: Panel discussionTitle: Structured Finance Solutions: Royalty, Credit and Other Alternative Financing Options for Life SciencesPresenter: Session Moderator — Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen Cell & Gene Meeting on the

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026. Citi 2026 Biopharma Back to School ConferenceLocation: JW Marriott Essex House, New York City, NYDate: Wednesday, September 9, 2026Time: 3:40–4:15 p.m. ETFormat: Fireside ChatPresenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen H.C. Wainwright 28th Annual Global Investment ConferenceLocation: Lotte New York Palace, New York City, NY Date: T

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor conferences in August 2026. Oppenheimer 4th Annual Biotech in the Berkshires Summit Location: Miraval Resort, Lenox, MADate: Tuesday, August 4, 2026Time: 12:30–1:10 p.m. ETSession Title: Beyond the Readout: Building Durable Value in Rare Diseases & Gen MedsFormat: Panel discussionPanelists: Shankar Musunuri, Pratik Shah, Ram Aiyar, Frank Gleeson, Allan ReineModerators: Leland Gershell, Managin

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in July 2026. Piper Sandler Virtual Ophthalmology Day – Fireside Chat Date: Friday, July 10, 2026Time: 10:00–10:25 a.m. EDTSpeaker: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, OcugenModerator: Biren Amin, Managing Director, Healthcare Equity Research, Piper Sandler & Co. OIS (Ophthalmology Innovation Source) Retina Innovation Summit Location: DoubleTree MontrealDate

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026. Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference Date: Thursday, June 4, 2026 Time: 2:30pm EDT Clinical Trials at the Summit 2026 Location: Fontainebleau Las VegasDate: Saturday, June 13, 2026Time: 10:19 – 10:39 am PDTInherited Retinal Diseases: Transforming the Future Through InnovationModerator: Peter KaiserPanelists: Lance Baldo, Pau

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific and investor conferences in May 2026. Retina World Congress Inherited and Rare Retinal Diseases SessionModerators: Kourous A. Rezaei, MD and Rishi P. Singh, MD, FASRSLocation: Grand BallroomDate: Thursday, May 14, 2026Time: 10:31 am – 11:10 a.m. EDT Stifel 2026 Virtual Ophthalmology Forum Location: VirtualDate: Tuesday, May 26, 2026 Time: 10:30 am – 10:55 a.m. EDT A webcast of the Stife

MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer's 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy. "I look forward to sharing our story with new audiences and building enthusiasm f

AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related DiseaseIssued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio, Inc. (OTCQB:AVAI), Lineage Cell Therapeutics, Inc. (NYSE:LCTX), Ocugen, Inc. (NASDAQ:OCGN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Longeveron Inc. (NASDAQ:LGVN)Key Takeaways:Avaí Bio (OTCQB:AVAI) and its joint venture partner Austrianova announced on April 7, 2026, that they will present their latest data from their α-Klotho anti-aging therapy at the Second Annual Klotho Conference in September, alongside Dr. Makoto Kuro-o — the physician-scientist widely recognized for discovering the Klotho gene [1

MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026, at The Westin St. Francis in San Francisco, CA."Year over year, Ocugen's presence at the JPM Healthcare Conference has evolved and we are delighted to share the potential of our modifier gene therapy platform along with clinical development progress," said Dr. Musunuri. "This premier conference is the optimal way to kick off Ocugen's ca

MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present at the Oppenheimer Movers in Rare Disease Summit taking place at the Sofitel New York on Thursday, December 11, 2025."For the second year in a row, we will join leaders advancing groundbreaking discoveries for rare disease at this significant meeting," said Dr. Musunuri. "I look forward to sharing more about Ocugen's novel modifier gene therapy platform with a gene-agnostic approach that has the potential to treat the entire diseas

MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen will present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex in Boca Raton, FL. "I look forward to sharing the meaningful progress Ocugen has made toward our goal of three BLAs in three years, along with updates on exciting near-term catalysts in 2026, during this important conference," said Dr. Musunuri. "NobleCon provides a forum t

MALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that executive leadership will present at the 2025 Cell & Gene Meeting on the Mesa, Chardan's 9th Annual Genetic Medicines Conference, and the 2025 Maxim Growth Summit. "These industry and investor meetings provide an excellent forum to share specifically how Ocugen is advancing toward our goal of three BLAs in the next three years," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We are excited to share our contribution toward bringing a new generation of gene therapies to m

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025 in New York, NY and a spotlight panel titled "The FDA Gauntlet: Strategies for a Successful Run at Approval" during Biotech on Tap 2025, September 24-26, 2025 in Munich, Germany. "Year after year, the H.C. Wainwright Global Investment Conference provides a great opportunity for us to m

MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present at the 2025 BIO International Convention at the Boston Convention & Exhibition Center from June 16-19, 2025. During the conference, Ocugen's leadership team will host meetings with potential partners and pharmaceutical executives to explore opportunities for the Company's novel modifier gene therapy platform targeting major blindness diseases with a one-time therapy for life. "We are excited to return to BIO this year on the heels of our recent execution of a bindin

MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2025 Cell & Gene Meeting on the Mediterranean being held April 15-17, 2025 at the Rome Cavalieri in Rome, Italy. "I look forward to sharing more on how Ocugen's modifier gene therapy platform can potentially change the treatment paradigm for major blindness diseases affecting hundreds of thousands to millions of patients by offering a one-time treatment for life," said Dr. Musunuri. "New techno

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the European Commission has provided a positive opinion from the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT) for OCU400 Advanced Therapy Medicinal Product (ATMP) classification. OCU400 is the first gene therapy to enter Phase 3 with a broad retinitis pigmentosa (RP) indication. "Receiving ATMP classification is another significant milestone toward bringing OCU400 to the market in Europe," said Dr. Shankar Mu

MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at the Oppenheimer Movers in Rare Disease Summit at the Westin Grand Central, New York on Thursday, December 12, 2024. "I have witnessed firsthand the impact that Ocugen's modifier gene therapies have made in the lives of patients with retinitis pigmentosa (RP) and Stargardt disease, which are inherited retinal diseases with significant unmet medical need," said

MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL—taking place December 3 - 4, 2024. "Every year, NobleCon showcases emerging growth companies from a variety of industries to a relevant investor audience," said Dr. Musunuri. "I look forward to shari

MALVERN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will join a panel discussion during the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, taking place from Tuesday, October 15 through Thursday, October 17, 2024. "The Maxim Healthcare Virtual Summit is a new opportunity for Ocugen," said Dr. Musunuri. "I look forward to introducing our first-in-class modifier gene therapy platform to a

MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2024 Cell & Gene Meeting on the Mesa being held October 7-9, 2024 at the Arizona Biltmore in Phoenix, AZ. "The Cell & Gene Meeting on the Mesa convenes industry decision-makers to address all aspects of translating cutting-edge science into effective treatment options—especially where no treatment options exist," said Dr. Musunuri. "The Alliance f

MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development, will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, at Chardan's 8th Annual Genetic Medicines Conference being held September 30-October 1, 2024 in New York, New York. "I am excited to speak about Ocugen's groundbreaking modifier gene therapy approach in treating retinal diseases and on the progress of our on

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen's Chief Scientific Officer, Head of Research & Development, will be among the featured speakers at the 5th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held September 10-12, 2024 in Boston, Mass. "There is tremendous potential for gene therapy to treat both rare retinal diseases and ophthalmic diseases affecting millions," said Dr. Upadhyay. "I look forward to sharing the development and clini

MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9-11, 2024 in New York, NY. "The H.C. Wainwright Global Investment Conference provides an excellent forum to engage with the investment community," said Dr. Musunuri. "I look forward to attending again this year and highlighting Ocugen's rec

MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has received notification from FDA to begin its expanded access program (EAP) for the treatment of adult patients, aged 18 and older, with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candidate. "Each clinical milestone achieved by OCU400 brings us closer to providing a potential one-time treatment for life to patients living with RP," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "With positi

MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). "Each clinical milestone achieved by OCU400 brings us closer to providing a one-time treatment for life to patients living with RP," said Dr. Shankar Musunuri, Chairman, CEO and Co-founder of Ocugen. "Dosing the first patient is especially significant and makes our dedicatio

MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024. During the conference, Ocugen's leadership team will host meetings with potential partners and pharmaceutical executives to explore opportunities for the Company's dynamic pipeline addressing unmet medical needs—particularly its first-in-class ophthalmic modifier gene therapy and regenerative cell therapy platforms. "We are excited

MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder, Ocugen, will present at The Citizens JMP Life Sciences Conference taking place at the New York Hilton Midtown from May 13 – 14, 2024. Additionally, Dr. Huma Qamar, Chief Medical Officer, Ocugen, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024. Details of the presentations are as follows: The Citi

MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference, presented by Noble Capital Markets, taking place from April 17 – 18, 2024. Details of the fireside chat are as follows: Date: Wednesday, April 17, 2024 Time: 10 a.m. ET Location: Presentation Track 1 Webcast: Available in the Events section of Ocugen website During the fireside chat and

MALVERN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ. "I look forward to joining my peers in discussing therapeutic approaches to treat inherited retinal diseases that can help slow or reverse degeneration regardless of the underlying genetic cause," said Dr. Musunuri. "Ocugen's modifier ge

MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the Abu Dhabi Family Office (ADFO) Summit being held February 29—March 1, 2024 at the Saadiyat Rotana Resort and Villas in Abu Dhabi, United Arab Emirates. "I'm honored to be an invited speaker among the prestigious gathering at the ADFO Summit," said Dr. Musunuri. "This is an excellent opportunity to share more about the potential of Ocugen's n

MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease is an orphan blindness disease that affects approximately 35,000 people in the United States alone. "This is an important clinical milestone for our first-in-class, potential one-time therapy for the treatment of Stargardt disease," said Dr. Arun Upadh

MALVERN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the BIO CEO & Investor Conference being held February 26-27, 2024, at the Marriott Marquis in New York City. Members of Ocugen's leadership team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated m

MALVERN, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will give the keynote: Future Innovations in Healthcare: From Dreaming to Community Health at the Pharma Market Research Conference (PMRC) from February 7-8, 2024 in Newark, NJ. "Since its beginnings, biotechnology has become more nuanced and personalized, and today, gene therapy in particular holds tremendous promise to cure debilitating conditions," said Dr. Musunuri. "I l

MALVERN, Pa., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present at NobleCon19 – Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL—taking place December 3 - 5, 2023. Details regarding the presentation and moderated Q&A are as follows: Date: Monday, December 4, 2023 Location: Presentation Room 1 Time: 2 p.m. ET   Following the pres

MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen's Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Dry AMD Therapeutic Development Summit, which is being held November 14-16, 2023 in Boston, Mass. PresentationSession: Gaining a Deeper Understanding of the Underlying Causes of Dry AMD to Inform Therapeutic Drug Development and Target SelectionTopic: Understanding the Complexity of Dry

MALVERN, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the 2023 Cell & Gene Meeting on the Mesa being held October 10-12, 2023 in Carlsbad, CA at the Park Hyatt Aviara Resort. Dr. Musunuri will provide an overview of Ocugen's clinical development programs, including the business strategy across its unique gene and cell therapy platforms, anticipated milestones, and more detail about the Comp

MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen's Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held October 3-5, 2023 in Boston, Mass. Dr. Upadhyay will be speaking during two sessions: WorkshopTopic: Endpoints for Gene Therapy Clinical Trials in OphthalmologyDate: October 3, 2023 Time: 9 a.m. - noon ET Presentatio

MALVERN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder and Dr. Huma Qamar, MPH, CMI, Head of Clinical Development and Medical Affairs will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst at the Chardan 7th Annual Genetic Medicines Conference being held October 2-3, 2023 in NYC. Details regarding the fireside chat are as follows: Date: October 2, 2023 L

MALVERN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at the annual Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in NYC. On the panel, Dr. Musunuri will join the CEO of Tarsier Pharma to discuss their companies' respective work toward developing novel therapies for hard-to-treat ocular diseases. In addition, members of Ocugen's executive

MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company's Chairman, CEO and Co-Founder, Shankar Musunuri, PhD, MBA, and Chief Scientific Officer, Head of Research, Development and Medical, Arun Upadhyay, PhD, will present at the American Association of Physicians of Indian Origin (AAPI) Convention and Scientific Assembly, July 6 – 9, 2023 in Philadelphia, PA. "The AAPI is an impressive organization that fosters the continued leadership of healthcare professionals of Indian orig

MALVERN, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present at the 2023 BIO International Convention taking place in Boston, Mass. from June 5-8, 2023. During the conference, members of the Ocugen team will host meetings with pharmaceutical executives to explore partnering and strategic opportunities for the Company's diverse and robust clinical pipeline—specifically its ophthalmic modifier gene therapy platform, including OCU400, and the inhalation vaccines portfolio. "

MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at the Nasdaq Market Site in Times Square, New York City. Details regarding Ocugen's fireside chat are as follows: Event: H.C. Wainwright BioConnect Investor Conference Date: Tuesday, May 2, 2023 Time: 11 – 11:30 a.m. EDT Location: Na

MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis, OCU410 for the treatment of dry age-related macular degeneration (dry AMD), and OCU410ST for the treatment of Stargardt disease; along with OCU200, a novel biologic candidate to treat diabetic macular edema (DME), at The Association for Research in Vision and Ophthalmology

MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company's Chief Scientific Officer, Arun Upadhyay, PhD, will present at the World Vaccine Congress being held April 3 – 6 in Washington D.C. "Current COVID-19 vaccines are limited by a lack of durability and inability to stop infection and transmission," said Dr. Upadhyay. "Inhaled vaccines have the potential to generate rapid mucosal immunity in respiratory pathways, limiting infection and transmission. I look forward to discussin

MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 at the Ritz Carlton, Laguna Niguel in Dana Point, California. Details regarding Ocugen's fireside chat are as follows: Event: 35th Annual Roth Conference Date: Monday, March 13, 2023 Time: 9 a.m. PDT Location: Healthcare Salon – Salon 5 – The Ritz

MALVERN, Pa., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company's Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the Retinal Vascular Disease Drug Development Summit at the Hilton Boston Logan Airport in Boston, Mass. from February 21-23, 2023. "I am very pleased that Dr. Upadhyay will share his expertise in this specific area of retinal disease research at the Retinal Vascular Disease Drug Development Summit," said Dr. Shankar Musunuri, Chairman, CEO & Co-Founder of Ocugen.

MALVERN, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Dr. Musunuri and members of Ocugen's executive team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the Company's business and clinical development strategy, recent corporate achievements, and ant

MALVERN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company's Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the 3rd Annual Dry AMD Therapeutics Summit at the Revere Hotel in Boston, Mass. from November 30-December 2, 2022. "I am very pleased that Dr. Upadhyay will share more about our Modifier Gene Therapy platform—a novel approach to treating retinal diseases—during the Dry AMD Summit," said Dr. Shankar Musunuri, Chairman, CEO & Co-Founder of Ocugen. "Our candidate, OC

MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month. "I look forward to sharing more about our Modifier Gene Therapy platform—a novel approach to treating inherited retinal disease—during the Meeting on the Mesa, and Dr. Hopkins will provide more on COVAXIN™— a whole-virion inactivated COVID-19 vaccine candidate currently in a Phase 2/3 immuno-bridging and broadening clinical trial with the U.S. FDA—at the Vaccines Summit," said Dr

MALVERN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the Chardan 6th Annual Genetic Medicines Conference being held October 3-4, 2022 in New York, NY. Details regarding Dr. Musunuri's fireside chat are as follows: Event: Chardan 6th Annual Genetic Medicines Conference Date: October 4, 2022 Time: 8:30 – 8:55 a.m. ETLocation: Westin Grand Central Hotel Webcast: Live

MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company's Chief Scientific Officer, Arun Upadhyay, PhD, will be among the featured speakers at the 3rd Annual Gene Therapy for Ophthalmic Disorders conference, which is being held Sept. 13-16 in Danvers, Massachusetts. Details regarding Dr. Upadhyay's presentation are as follows: Event: 3rd Annual Gene Therapy for Ophthalmic Disorders ConferenceTopic:Highlighting the Modifier Gene Therapy Approach for the Treatment of Retinitis PigmentosaD

MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 in New York, NY. Details regarding Dr. Musunuri's fireside chat are as follows: Event: H.C. Wainwright 24th Annual Global Investment ConferenceDate:September 12, 2022Time:3:30 – 4:00 p.m. ETLocation:Lotte New York Palace HotelW

MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17. A video webcast of the presentation will be available on demand beginning at 7:00 a.m. ET on August 17, 2022 for those registered for the event and will be available on the events page of the Ocugen investor site. The webcast replay will be archive

MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that Michael Shine, Ocugen's Senior Vice President, Commercial, will present at the 2022 BIO International Convention being held in San Diego, California, from June 13-16, 2022. The Company presentation, which is scheduled for Monday, June 13, at 4:45 p.m. PT in Meeting Room 1 of the San Diego Convention Center, will focus on Ocugen's robust clinical pipeline, including its COVID-19 vaccine candidate, COVAXIN™ (BBV152), its modifier gene therapy programs, and its new ce

MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will participate in an in-person fireside chat at the H.C. Wainwright Global Investment Conference, on May 24, 2022, at 1:30pm ET in Miami Beach, Florida. Registration is available for those who want to watch the presentation virtually. A replay of the fireside chat will be available through the Investor's section of the Ocugen website starting on May 24 and for approximately 90 days following the conference

MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the Company's Phase 2/3 clinical trial, OCU-002, for COVAXIN™ (BBV152). "We're extremely pleased that we can proceed with our clinical trials for COVAXIN™, our whole virus inactivated COVID-19 vaccine candidate. The need for delivering an additional, differentiated vaccine option, we believe, remains a priority," said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen, Inc. "Thank you to o

MALVERN, Pa., April 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will present on-location at NobleCon18 - Noble Capital Markets' Eighteenth Annual Investor Conference. EventNoble Capital Markets' Eighteenth Annual Investor ConferenceDateApril 21, 2022Presentation10:30AM Eastern TimeOn-site locationTerrace Ballroom BHard Rock Hotel & Casino, Hollywood, Florida A high-definition, video webcast of the presentation will be available the following day on Ocugen's website and

MALVERN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, Inc., will be presenting at the 34th Annual Roth Conference. Event34th Annual ROTH ConferenceDateMarch 14, 2022Presentation11:00am Pacific Time (2:00pm Eastern Time)LocationDana Point, CA This year's event will consist of 1-on-1/small group meetings, analyst-selected fireside chats, thematic industry panels, and on-demand presentations by